![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | increases expression | ISO | RGD:1557809 | 6480464 | 1, 2-Dimethylhydrazine results in increased expression of ERO1B mRNA | CTD | PMID:22206623 | 17beta-estradiol | decreases expression | ISO | RGD:1557809 | 6480464 | Estradiol results in decreased expression of ERO1B mRNA | CTD | PMID:19484750 | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | ISO | RGD:1344502 | 6480464 | Dihydrotestosterone results in increased expression of ERO1B mRNA | CTD | PMID:29581250 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1557809 | 6480464 | Tetrachlorodibenzodioxin affects the expression of ERO1B mRNA | CTD | PMID:24680724 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ERO1B mRNA | CTD | PMID:34747641 | 3,4-methylenedioxymethamphetamine | increases expression | ISO | RGD:1557809 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of ERO1B mRNA | CTD | PMID:20188158 | 3-chloropropane-1,2-diol | increases expression | EXP | | 6480464 | alpha-Chlorohydrin results in increased expression of ERO1B protein | CTD | PMID:34915118 | 4,4'-diaminodiphenylmethane | increases expression | ISO | RGD:1557809 | 6480464 | 4, 4'-diaminodiphenylmethane results in increased expression of ERO1B mRNA | CTD | PMID:18648102 | acrylamide | increases expression | ISO | RGD:1344502 | 6480464 | Acrylamide results in increased expression of ERO1B mRNA | CTD | PMID:32763439 | aflatoxin B1 | decreases expression | ISO | RGD:1557809 | 6480464 | Aflatoxin B1 results in decreased expression of ERO1B mRNA | CTD | PMID:19770486 | all-trans-retinoic acid | increases expression | ISO | RGD:1344502 | 6480464 | Tretinoin results in increased expression of ERO1B mRNA | CTD | PMID:23724009 | all-trans-retinoic acid | decreases expression | ISO | RGD:1344502 | 6480464 | Tretinoin results in decreased expression of ERO1B mRNA | CTD | PMID:33167477 | amiodarone | decreases expression | ISO | RGD:1557809 | 6480464 | Amiodarone results in decreased expression of ERO1B mRNA | CTD | PMID:24535564 | atrazine | increases expression | ISO | RGD:1344502 | 6480464 | Atrazine results in increased expression of ERO1B mRNA | CTD | PMID:22378314 | benzo[a]pyrene | decreases expression | ISO | RGD:1344502 | 6480464 | Benzo(a)pyrene results in decreased expression of ERO1B mRNA | CTD | PMID:22316170, PMID:32234424 | benzo[a]pyrene | decreases expression | ISO | RGD:1557809 | 6480464 | Benzo(a)pyrene results in decreased expression of ERO1B mRNA | CTD | PMID:19770486 | benzo[a]pyrene | decreases methylation | ISO | RGD:1344502 | 6480464 | Benzo(a)pyrene results in decreased methylation of ERO1B promoter | CTD | PMID:27901495 | bisphenol A | increases expression | ISO | RGD:1344502 | 6480464 | bisphenol A results in increased expression of ERO1B mRNA | CTD | PMID:29275510 | bisphenol A | increases expression | ISO | RGD:1557809 | 6480464 | bisphenol A results in increased expression of ERO1B mRNA | CTD | PMID:30951980 | bromobenzene | increases expression | EXP | | 6480464 | bromobenzene results in increased expression of ERO1B mRNA | CTD | PMID:32479839 | cadmium atom | multiple interactions | ISO | RGD:1344502 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ERO1B mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | RGD:1344502 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ERO1B mRNA | CTD | PMID:35301059 | captan | decreases expression | ISO | RGD:1557809 | 6480464 | Captan results in decreased expression of ERO1B mRNA | CTD | PMID:31558096 | carbon nanotube | increases expression | ISO | RGD:1557809 | 6480464 | Nanotubes, Carbon results in increased expression of ERO1B mRNA | CTD | PMID:25620056 | choline | multiple interactions | ISO | RGD:1557809 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ERO1B, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ERO1B gene | CTD | PMID:20938992 | ciguatoxin CTX1B | affects expression | ISO | RGD:1557809 | 6480464 | Ciguatoxins affects the expression of ERO1B mRNA | CTD | PMID:18353800 | cisplatin | multiple interactions | ISO | RGD:1344502 | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of ERO1B mRNA | CTD | PMID:27392435 | copper(II) sulfate | increases expression | ISO | RGD:1344502 | 6480464 | Copper Sulfate results in increased expression of ERO1B mRNA | CTD | PMID:19549813 | crocidolite asbestos | decreases expression | ISO | RGD:1557809 | 6480464 | Asbestos, Crocidolite results in decreased expression of ERO1B mRNA | CTD | PMID:29279043 | cyclosporin A | increases expression | ISO | RGD:1344502 | 6480464 | Cyclosporine results in increased expression of ERO1B mRNA | CTD | PMID:19159671 more ... | dinophysistoxin 1 | increases expression | ISO | RGD:1344502 | 6480464 | dinophysistoxin 1 results in increased expression of ERO1B mRNA | CTD | PMID:28939011 | dioxygen | increases expression | ISO | RGD:1557809 | 6480464 | Oxygen deficiency results in increased expression of ERO1B | CTD | PMID:12752442 | dorsomorphin | multiple interactions | ISO | RGD:1344502 | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1344502 | 6480464 | Doxorubicin results in decreased expression of ERO1B mRNA | CTD | PMID:29803840 | ethanol | affects splicing | ISO | RGD:1557809 | 6480464 | Ethanol affects the splicing of ERO1B mRNA | CTD | PMID:30319688 | fenpyroximate | increases expression | ISO | RGD:1344502 | 6480464 | fenpyroximate results in increased expression of ERO1B mRNA | CTD | PMID:33512557 | folic acid | multiple interactions | ISO | RGD:1557809 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ERO1B, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ERO1B gene | CTD | PMID:20938992 | folic acid | decreases expression | ISO | RGD:1557809 | 6480464 | Folic Acid results in decreased expression of ERO1B mRNA | CTD | PMID:25629700 | folpet | decreases expression | ISO | RGD:1557809 | 6480464 | folpet results in decreased expression of ERO1B mRNA | CTD | PMID:31558096 | genistein | increases expression | ISO | RGD:1344502 | 6480464 | Genistein results in increased expression of ERO1B mRNA | CTD | PMID:26865667 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of ERO1B mRNA | CTD | PMID:33387578 | hydralazine | multiple interactions | ISO | RGD:1344502 | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of ERO1B mRNA | CTD | PMID:17183730 | L-methionine | multiple interactions | ISO | RGD:1557809 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of and results in decreased expression of ERO1B, [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of ERO1B gene | CTD | PMID:20938992 | mercury dibromide | multiple interactions | ISO | RGD:1344502 | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA | CTD | PMID:27188386 | methylisothiazolinone | increases expression | ISO | RGD:1344502 | 6480464 | 2-methyl-4-isothiazolin-3-one results in increased expression of ERO1B mRNA | CTD | PMID:31629900 | N-nitrosodiethylamine | increases expression | ISO | RGD:1557809 | 6480464 | Diethylnitrosamine results in increased expression of ERO1B mRNA | CTD | PMID:24535843 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of ERO1B mRNA | CTD | PMID:33387578 | phenobarbital | affects expression | ISO | RGD:1557809 | 6480464 | Phenobarbital affects the expression of ERO1B mRNA | CTD | PMID:23091169 | phenylmercury acetate | multiple interactions | ISO | RGD:1344502 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA | CTD | PMID:27188386 | pirinixic acid | multiple interactions | ISO | RGD:1344502 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of ERO1B mRNA | CTD | PMID:19710929 | pirinixic acid | multiple interactions | ISO | RGD:1557809 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ERO1B mRNA | CTD | PMID:19710929 | pirinixic acid | decreases expression | ISO | RGD:1557809 | 6480464 | pirinixic acid results in decreased expression of ERO1B mRNA | CTD | PMID:23811191 | pregnenolone 16alpha-carbonitrile | decreases expression | ISO | RGD:1557809 | 6480464 | Pregnenolone Carbonitrile results in decreased expression of ERO1B mRNA | CTD | PMID:28903501 | propiconazole | increases expression | ISO | RGD:1557809 | 6480464 | propiconazole results in increased expression of ERO1B mRNA | CTD | PMID:21278054 | resorcinol | decreases expression | ISO | RGD:1344502 | 6480464 | resorcinol results in decreased expression of ERO1B mRNA | CTD | PMID:22623647 | resveratrol | multiple interactions | ISO | RGD:1344502 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of ERO1B mRNA | CTD | PMID:23557933 | SB 431542 | multiple interactions | ISO | RGD:1344502 | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sodium arsenite | decreases expression | ISO | RGD:1344502 | 6480464 | sodium arsenite results in decreased expression of ERO1B mRNA | CTD | PMID:28595984 | sodium arsenite | affects expression | ISO | RGD:1344502 | 6480464 | sodium arsenite affects the expression of ERO1B mRNA | CTD | PMID:34032870 | sunitinib | increases expression | ISO | RGD:1344502 | 6480464 | Sunitinib results in increased expression of ERO1B mRNA | CTD | PMID:31533062 | testosterone | decreases expression | ISO | RGD:1557809 | 6480464 | Testosterone deficiency results in decreased expression of ERO1B mRNA | CTD | PMID:33848595 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of ERO1B mRNA | CTD | PMID:30723492, PMID:31150632 | tetrachloromethane | increases expression | ISO | RGD:1557809 | 6480464 | Carbon Tetrachloride results in increased expression of ERO1B mRNA | CTD | PMID:31919559 | thapsigargin | increases expression | ISO | RGD:1344502 | 6480464 | Thapsigargin results in increased expression of ERO1B mRNA | CTD | PMID:22378314 | titanium dioxide | increases expression | ISO | RGD:1557809 | 6480464 | titanium dioxide results in increased expression of ERO1B mRNA | CTD | PMID:23557971 | Tributyltin oxide | increases expression | ISO | RGD:1344502 | 6480464 | bis(tri-n-butyltin)oxide results in increased expression of ERO1B mRNA | CTD | PMID:21601586 | trichloroethene | increases expression | EXP | | 6480464 | Trichloroethylene results in increased expression of ERO1B mRNA | CTD | PMID:33387578 | trichostatin A | multiple interactions | ISO | RGD:1344502 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERO1B mRNA | CTD | PMID:27188386 | trichostatin A | decreases expression | ISO | RGD:1344502 | 6480464 | trichostatin A results in decreased expression of ERO1B mRNA | CTD | PMID:26272509 | tunicamycin | increases expression | ISO | RGD:1344502 | 6480464 | Tunicamycin results in increased expression of ERO1B mRNA | CTD | PMID:22378314, PMID:29453283 | tunicamycin | increases expression | ISO | RGD:1557809 | 6480464 | Tunicamycin results in increased expression of ERO1B mRNA | CTD | PMID:12752442 | urethane | increases expression | ISO | RGD:1344502 | 6480464 | Urethane results in increased expression of ERO1B mRNA | CTD | PMID:28818685 | valproic acid | multiple interactions | ISO | RGD:1344502 | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of ERO1B mRNA | CTD | PMID:17183730 | valproic acid | affects expression | ISO | RGD:1344502 | 6480464 | Valproic Acid affects the expression of ERO1B mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1557809 | 6480464 | Valproic Acid results in decreased expression of ERO1B mRNA | CTD | PMID:24535564 | valproic acid | increases expression | ISO | RGD:1344502 | 6480464 | Valproic Acid results in increased expression of ERO1B mRNA | CTD | PMID:23179753 more ... | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of ERO1B mRNA | CTD | PMID:23034163 | |